



Agiwal & Associates

CHARTERED ACCOUNTANTS

Head Office : D-6/9, Upper Ground Floor, Rana Pratap Bagh, Delhi-110007 (INDIA)
Phone : 011-41011281, 43512990 E-mail : caagiwal68@gmail.com, office@agiwalassociates.in

Independent Auditor's review report on the Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026 of Park Medi World Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To The Board of Directors,
Park Medi World Limited,**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Park Medi World Limited** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), for the quarter ended June 30, 2026 (the "Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Parent's management is responsible for preparation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34") "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Parent's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the subsidiaries and associates listed in Annexure-I.
5. (a) Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

(b) The Statement includes the results for the corresponding quarter ended June 30, 2025 as reported in the previously issued Statement, which were not subject to limited review.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to



be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The accompanying Statement includes the interim financial results of 19 subsidiaries which has been reviewed by other auditors whose unaudited interim financial results include total revenue of Rs.3749.42 million (before consolidation adjustments), total net profit after tax of Rs.717.68 million (before consolidation adjustments), total comprehensive income of Rs.714.11 million (before consolidation adjustments), for the quarter ended June 30, 2026, and whose reports have been furnished to us by the parent's Management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.

The interim financial results of 2 subsidiaries have been reviewed by the Management of the Company, whose financial results include total revenue of Rs.163.15 million, total net profit after tax of Rs.26.00 million, total comprehensive income of Rs.26.00 million, for the quarter ended June 30, 2026.

Our Conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditor.

For Agiwal & Associates
Chartered Accountants
FRN No: 000181N



P.C. Agiwal
Partner
Membership Number: 080475

Place: Gurugram
Date: August 03, 2026
UDIN: 26080475JKIYOL3362

Annexure-I

List of entities included in unaudited consolidated financial results.

S. No.	Name of component	Country	Relationship
1	Park Medi World Limited	India	Parent
2	Park Medicentres & Institutions Private Limited	India	Subsidiary
3	Aggarwal Hospital & Research Services Private Limited	India	Subsidiary
4	Park Medicity India Private Limited	India	Subsidiary
5	Park Medical Centre Private Limited	India	Subsidiary
6	Park Medicity (North) Private Limited	India	Subsidiary
7	Park Medicity (World) Private Limited	India	Subsidiary
8	Park Medicity (NCR) Private Limited	India	Subsidiary
9	Park Imperial Medi World Private Limited	India	Subsidiary
10	Park Elite Medi World Private Limited	India	Subsidiary
11	Blue Heavens Healthcare Private Limited	India	Subsidiary
12	Kailash Super Speciality Hospital Private Limited	India	Subsidiary
13	Umkal Heathcare Private Limited	India	Subsidiary
14	SVPD Heathcare Private Limited	India	Subsidiary
15	K P S Wellness Private Limited	India	Subsidiary
16	Mahip Hospitals Private Limited	India	Step-down subsidiary
17	DMR Hospitals Private Limited	India	Step-down subsidiary
18	Park Medicity (Haryana) Private Limited	India	Step-down subsidiary
19	RGS Helathcare Limited	India	Step-down subsidiary
20	Devina Derma Private Limited*	India	Step-down subsidiary
21	Ratangiri Innovations Private Limited	India	Step-down subsidiary
22	Narsingh Hospital & Heart Institute Private Limited	India	Step-down subsidiary
23	Durha Vitrak Private Limited	India	Step-down subsidiary

*The company ceases to be subsidiary with effect from June 5th, 2026 due to divestment.



PARK MEDI WORLD LIMITED

(Formerly known as Park Medi World Private Limited)

(CIN: L85110DL2011PLC212901)

Registered Office: 12, Meera Enclave, Near Keshopur Bus Depot., Outer Ring Road, New Delhi-110018
Website: www.parkhospital.in; Email: company.secretary@parkhospital.in Phone No. 91-124-6960000

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ in millions, except per share data)

Particulars	Quarter Ended		Year Ended	
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
	Unaudited	Audited	Unaudited	Audited
I Income				
Revenue from operations	4,757.09	4,604.13	3,988.45	16,793.56
Other income	76.46	75.03	68.72	316.09
Total Income	4,833.55	4,679.16	4,057.17	17,109.65
II Expenses				
Cost of material/Service consumed	771.24	784.34	699.39	2,950.61
Changes in inventories of stock	(8.67)	11.91	0.80	7.45
Employee benefit expenses	924.07	861.64	767.79	3,233.97
Professional and consultancy fees	756.05	716.20	603.22	2,570.74
Finance costs	98.10	139.75	151.33	588.85
Depreciation and amortisation expense	188.40	175.06	147.71	624.62
Other expenses	1,053.52	956.35	867.94	3,587.57
Total Expenses	3,782.71	3,645.26	3,238.18	13,563.81
III Profit/(Loss) before exceptional items and tax (I-II)	1,050.84	1,033.90	818.99	3,545.84
IV Exceptional items	-	-	-	-
V Profit/(Loss) before tax (III-IV)	1,050.84	1,033.90	818.99	3,545.84
VI Tax expenses				
Current tax	260.98	197.42	167.48	822.45
Deferred tax charge/(benefit)	(93.40)	68.25	(3.55)	(14.51)
Income tax relating to previous years	(2.67)	0.45	-	2.33
	164.91	266.12	163.93	810.27
VII Profit/(Loss) after tax (V-VI)	885.93	767.78	655.06	2,735.57
VIII Other comprehensive income/(loss)				
Items that will not be reclassified to profit or loss				
- Remeasurement of employee defined benefit plans	(7.76)	4.15	(1.04)	12.88
- Income tax relating to above	1.95	(0.30)	0.26	(3.24)
	(5.81)	3.85	(0.78)	9.64
IX Total comprehensive income/(loss) (VII+VIII)	880.12	771.63	654.28	2,745.21
X Profit/(Loss) for the period attributable to:				
Owners of the parent	825.07	708.64	579.83	2,581.20
Non- controlling Interest	60.86	59.14	75.23	154.37
	885.93	767.78	655.06	2,735.57
XI Other Comprehensive Income/(Loss) for the period attributable to:				
Owners of the parent	(5.69)	3.61	(0.80)	9.17
Non- controlling Interest	(0.12)	0.24	0.02	0.47
	(5.81)	3.85	(0.78)	9.64
XII Total Comprehensive Income/(Loss) for the period attributable to:				
Owners of the parent	819.38	712.25	579.04	2,590.37
Non- controlling Interest	60.74	59.38	75.24	154.84
	880.12	771.63	654.28	2,745.21
Paid up Equity Share Capital (Face Value: ₹ 2 each per share)	863.86	863.86	768.80	863.86
Other Equity excluding Revaluation Reserve				19,236.51
Earnings per Share (EPS) (not annualised)				
(i) Basic (₹)	2.05	1.78	1.70	6.87
(ii) Diluted (₹)	2.05	1.78	1.70	6.87

See accompanying notes to the financial results



For and on behalf of the Board of Directors
Park Medi World Limited


[Signature]
Dr. Sanjay Sharma
Chief Executive Officer & Whole Time Director
DIN: 07181328

Place: Gurugram
Date: August 03, 2026

Notes to the unaudited Consolidated financial results for the quarter ended June 30, 2026

1. The unaudited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 "Interim Financial Reporting" notified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. The unaudited Consolidated financial results ('the Statement') of Park Medi World Limited ('the company') for the quarter ended June 30, 2026 were reviewed by the Audit committee on August 03, 2026 and approved by the Board of Directors at its meeting held on August 03, 2026 in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the statutory auditors of the company who have issued an unmodified opinion on the same.
3. The Company has launched a 350 bedded advanced multi-super specialty hospital at Panchkula on April 10, 2026. The Panchkula hospital is equipped with advanced diagnostics, modular operation theatres, critical care infrastructure, and will deliver comprehensive care across key specialties including oncology, neurosciences, orthopaedics, cardiology, and critical care including robotic-assisted procedures.
4. RGS Healthcare Limited, the step down subsidiary of the Company, has proposed the expansion of its Mohali unit from 350 beds to 500 beds. The overall cost of expansion will be approx. ₹ 400 millions which is proposed to be funded through internal accruals.

Umkal Healthcare Private Limited, the wholly owned subsidiary of the Company, has proposed the expansion of its existing 225-bedded Park Hospital in Palam Vihar, Gurugram, with addition of 100 new beds. The newly expanded facility will be branded as "Park Hospital Platinum" and the proposed capacity addition is to be completed by November 2026. Overall cost of additional beds will be approx. ₹ 250 millions which is proposed to be funded from internal accruals.
5. Park Medicenters and Institutions Private Limited, a subsidiary of the Company, has incorporated a wholly owned subsidiary in the name of "Heal Plus Medical Services Private Limited" having CIN: U47721DC2026PTC471594, on May 20, 2026. The new subsidiary has not commenced business operations as of June 30, 2026, and hence has no financial impact on the consolidated results.
6. Aggarwal Hospital and Research Services Private Limited, a wholly owned subsidiary of the Company, has divested its entire 55% shareholding in Devina Derma Private Limited, a subsidiary of Aggarwal Hospital and Research Services Private Limited, for a consideration of ₹ 0.60 million. The transaction was completed on June 05, 2026 and since then Devina Derma Private Limited ceased to be a subsidiary of Aggarwal Hospital and Research Services Private Limited, and consequently, of the Company. This divestment has been undertaken by the company as a strategic management decision.
7. The Group's business activity primarily falls within a single reportable business segment namely "Healthcare Service" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind AS 108- "Segment Reporting". The Group does not distinguish revenues, costs and expenses between segments in its internal reporting, and report costs and expenses by nature as a whole. The Board of Directors (Chief Operating Decision Maker ("CODM")) reviews the Consolidated Financial information when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group operates and manages its business as a single segment mainly through the sale of healthcare services. The Group operates in one geographic segment namely "within India" and hence no separate information for geographic segment wise disclosure is required.



8. The utilisation of the IPO proceeds is summarised below:

(₹ in millions)

Object of the issue as per prospectus:	Utilisation planned as per prospectus	Utilised up to June 30, 2026	Amount pending for utilisation as on June 30, 2026
Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries	3,800.00	3,800.00	-
Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) Private Limited	605.00	195.19	409.81
Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens Healthcare Private Limited and Ratnagiri Innovations Private Limited	274.59	36.08	238.51
Unidentified inorganic acquisitions and general corporate purposes	2,453.18	2,453.18	-
Total	7,132.77	6,484.45	648.32
Issue expenses towards IPO	567.23	567.23	-
Grand Total	7,700.00	7,051.68	648.32

There is no deviation in the utilization of proceeds from the objects stated in the offer document and there is no variation in the terms of contract referred to in the prospectus.

9. Subsequent event: The Company has successfully acquired 80% shareholding of V3 Healthcare Private Limited on July 31, 2026 which operates a multi-specialty Hospital in the name of "The Medicity Hospital - Rudrapur", Uttaranchal having capacity of 330 beds. Remaining 20% will be acquired by April 30, 2030. Overall cost of acquisition is approx. ₹ 1,770 millions. Consequent to this acquisition, V3 Healthcare Private Limited has become a subsidiary of the Company. Further, the Hospital has been launched on August 2, 2026.
10. During the quarter ended June 30, 2026 the Company did not receive any investor complaint. No complaints were pending resolution as on June 30, 2026. The Company has adequate systems and processes in place to address investor grievances in a timely manner in compliance with Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.
11. Previous period figures have been regrouped / reclassified wherever necessary to conform to current period classification and rounding off errors have been ignored.
12. The unaudited Consolidated financial results for the quarter ended June 30, 2026 are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed.

